HTLV-III Serology in Hemophilia: Relationship with Immunologic Abnormalities

Joan C. Gill  
*Children's Hospital of Wisconsin*

Jay E. Menitove  
*Community Blood Center, gch@cbckc.org*

Philip R. Anderson

James T. Casper  
*Children's Hospital of Wisconsin*

Sushilkumar G. Devare

See next page for additional authors

Follow this and additional works at: [http://digitalcommons.unl.edu/virologypub](http://digitalcommons.unl.edu/virologypub)
Authors
We investigated the relationship of the presence of antibodies to HTLV-III and immunologic abnormalities in patients with hemophilia. Serum antibodies to HTLV-III were analyzed by ELISA assay, immunoprecipitation of labeled cell extracts, and immunoprecipitation of purified HTLV-III p24. Thirty-four (61%) of the total group (n = 56) had antibody to HTLV-III; 34 (76%) of 45 patients given commercial factor VIII preparations were seropositive, compared with none of 11 patients treated exclusively with cryoprecipitate obtained from volunteer blood donors. Of patients who were seropositive for HTLV-III antibody, 94% had abnormal T4/T8 ratios, and 33% of those whose serum was antibody negative had abnormal T4/T8 ratios; five patients, each antibody positive, have lymphadenopathy syndrome. Sequential studies in a subset of patients indicate that there is a changing pattern of antibody production to HTLV-III antigens after seroconversion.

AIDS-related abnormalities were noted in hemophilic patients. Furthermore, hemophilic patients given concentrates from the United States have been found to have a high prevalence of antibody to LAV/HTLV-III, and the appearance of antibody appears to coincide with the AIDS epidemic. To determine whether the immunologic abnormalities are associated with evidence of infection or exposure to the retrovirus, we investigated the presence of serum antibody to one of the isolates, HTLV-III, in patients with hemophilia.

See related article, p. 504, and letter, p. 631.

AIDS Acquired immune deficiency syndrome
HTLV-III Human T cell lymphotropic virus type III
ELISA Enzyme-linked immunosorbent assay
LAV Lymphadenopathy-associated virus
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

METHODS

All patients enrolled in the comprehensive care program of the Great Lakes Hemophilia Foundation who live within a 60-mile radius of Milwaukee were contacted to participate in the study; 43 patients were selected on
the basis of availability to have a sample of blood taken during the 2-week period of sampling. Thirteen additional patients were selected from the Green Bay satellite center when they were evaluated for other reasons during the same period. The patients were divided into two groups, those in whom hemorrhages were treated with commercial lyophilized concentrate and those exclusively given cryoprecipitate prepared from the plasma of volunteer blood donors at the Blood Center of Southeastern Wisconsin. Histories were obtained from all patients, and all were specifically examined for the presence of lymphadenopathy and hepatosplenomegaly. Control groups included normal adults, 15 parents of hemophilic boys, five spouses of hemophilic men, and 50 homosexual men seen at a Milwaukee community medical clinic.

Clinical laboratory studies. Complete blood counts and platelet counts were performed on an ELT-8DS Blood Analyzer (Ortho Diagnostic Systems, Westwood, Mass.). White blood cell differential counts were performed by visualization of cells on a Wright-stained blood smear. Serum IgG, IgM, and IgA concentrations were determined by radial immunodiffusion (Helena Laboratories, Beaumont, Texas). Enumeration of lymphocyte subsets was determined by indirect immunofluorescence with OKT monoclonal antibodies incubated with the Ficoll-Hypaque separated mononuclear cell preparation from venous blood, as previously described.5

Virus and cells. Uninfected HT-9 cells and HT-9 cells chronically infected with HTLV-III were kindly provided by R. C. Gallo, National Cancer Institute, Bethesda, Maryland. Virus was concentrated one thousandfold, purified by density gradient centrifugation, and disrupted by sonication in the presence of 1% Triton X-100 and 0.05 M Tris-HCl (pH 9.0). The solution of disrupted virus was clarified by centrifugation at 100,000 × g for 1 hour.

HTLV-III ELISA. In brief, the assay was performed by incubation of test sera with solubilized HTLV-III antigen bound to wells of microtiter plates or antigen-coated polystyrene beads (Abbott Laboratories, North Chicago, Illinois). After washing the plates or beads, alkaline phosphatase-conjugated goat anti-human IgG was added, and after further washing the substrate p-nitrophenyl phosphate was used to quantitate the antibody bound.

Immunoprecipitation of labeled cell extracts. Cultures of 10⁷ HT-9 cells and 10⁷ HT-9 cells chronically infected with HTLV-III were centrifuged and washed twice in methionine- and cysteine-free medium, resuspended in 10 ml of the same medium, and allowed to incubate at 37°C for 30 minutes. Cells were then collected by centrifugation and placed in 10 ml of medium containing 100 μCi/ml 35-S methionine and 100 μCi/ml 35-S cysteine. Cells were incubated for 4 hours at 37°C in this medium, harvested by centrifugation, and washed twice in complete media. Cells were resuspended in lysis buffer containing 10 mM sodium phosphate, pH 7.5, 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate at a concentration of 4 x 10⁶ cells/ml. Ten microliters of test serum was incubated with 200 μl aliquots of lysate for 30 minutes at 0°C; Staphylococcus aureus protein A bound to Sepharose beads (Pharmacia, Piscataway, N.J.) was then used to recover antigen-antibody complexes, which were then analyzed by SDS-PAGE as previously described.17

p-24 Radioimmunoassay. Double-antibody precipitation with ¹²⁵I-labeled HTLV-III p24 was performed as previously described.18 In brief, the p24 protein was purified to homogeneity by phosphocellulose column chromatography and labeled with ¹²⁵I (30 μCi/μg) by Iodo-beads (Pierce Chemical Co., Rockford, Ill.). Serial dilutions of test sera were incubated with ¹²⁵I-labeled purified p24, followed by precipitation of antigen-antibody complexes by incubation with anti-human IgG antisera, centrifugation to recover precipitates, and counting in an ANSA gamma counter (Abbott Laboratories). A sample was considered positive if precipitated counts were five times background.

RESULTS

Antibody to HTLV-III was detected by ELISA in 34 (61%) of 56 hemophilic patients (Table I). Among 45 patients who received commercial lyophilized concentrate, 34 (76%) had antibody to HTLV-III, compared with none of 11 patients treated exclusively with cryoprecipitate. Neither of the two patients with hemophilia B treated with factor IX concentrate had antibody, but three of four patients with inhibitors to factor VIII, all treated with
HIV Serology in Hemophilia: Relationship with Immunologic Abnormalities

Both factor VIII and factor IX concentrate, had antibody. All patients with positive results by ELISA had antibody to viral glycoproteins gp120 and gp160, as demonstrated by radioimmunoprecipitation of labeled cell extracts (Figure 1). Similarly, all patients who had positive ELISA results had antibodies capable of recognizing \(^{125}\)I-labeled HTLV-III p24; however, titers of these anti-p24 antibodies varied as much as a thousandfold. Those with low antibody titers to purified p24 also lacked detection of anti-p24 by radioimmunoprecipitation of labeled cell extracts. Furthermore, the ability of these sera to precipitate pp55 varied (Figure 1). This result is not unexpected, because pp55 is a precursor protein consisting of the p24, p17, and p15 gag proteins of the virus. Thus, sera with a low titer to p24 may be unable to precipitate quantities of pp55 if antibodies to other gag proteins are not present.

Chi-square analysis of immunologic status and HTLV-III serology revealed five statistically significant factors (Table II). Each of five patients with persistent generalized lymphadenopathy had HTLV-III antibody. Decreased platelet counts, decreased T4 lymphocytes, decreased T4/T8 ratios, and elevated serum IgG concentrations were associated with antibody to HTLV-III, whereas abnormal IgM and IgA and elevated T8 lymphocytes were not associated with HTLV-III antibodies.

Sequential studies were performed on samples stored since January 1982 from 17 of the patients who were seropositive for HTLV-III; only three had results on earlier samples. In November 1982, patient 1 was seronegative for HTLV-III antibody and had a normal T4/T8 ratio. Two months later, antibody was detectable and his T4/T8 ratio decreased. Antibody and T4/T8 ratio have remained abnormal, and in May 1984, 17 months after the appearance of HTLV-III antibodies, persistent lymphadenopathy developed. Patient 2 had a similar course, with seroconversion in October 1982, a decrease in T4/T8 ratio at his next evaluation, and development of generalized lymphadenopathy 22 months later. After the appearance of antibody to HTLV-III in January 1983, a third patient developed an abnormal T4/T8 ratio in November 1983, and had an episode of localized herpes zoster in February 1985.

The pattern in these three patients of serum reactivity to various HTLV-III viral proteins by immune precipitation of HTLV-III proteins is demonstrated in Figure 2. None of the initial samples precipitated viral proteins, whereas all three precipitated the gp 160/120, pp55, and p24 viral proteins when studied most recently. The patients

**Fig. 1.** Immunoprecipitation of 35-S methionine- and 35-S cysteine-labeled HTLV-III antigens by sera from patients with hemophilia. Molecular weight standards (kD) are in lane A, with corresponding molecular weight to left of autoradiogram; molecular weights of HTLV-III antigens are shown on right. Immunoprecipitation of extract of HT-9 cells without HTLV-III is shown in lane J. Note variable patterns of reactivity among patients. All patient sera immunoprecipitate gp 160/120. Patient D serum has antibody to p24 but decreased reactivity to pp55; patient B serum precipitates gp 120/160 only.
with lymphadenopathy precipitated relatively more pp55 and p24 than did the patient with herpes zoster. In contrast, a fourth patient, initially seropositive at the onset of the study, had an early response to p24, which was absent 18 months later; lymphadenopathy also has and more recently the onset of significant thrombocytopenia (platelet count <50,000/μl).

Selected family members were examined to some insight into the transmissibility of HTLV-III. Fifteen parents of hemophilic boys (the sons of 10 were seropositive for HTLV-III antibody) who prepared and administered treatment product were seronegative for HTLV-III antibody. Similarly, none of five spouses of hemophilic patients (two positive for HTLV-III antibody) had HTLV-III antibody. In contrast, 14 (28%) of 50 homosexual men seen at a community medical clinic in Milwaukee were seropositive for HTLV-III by ELISA.

**DISCUSSION**

Evidence for a human retroviral cause for AIDS has recently accumulated. The original isolates, HTLV-III and LAV, are likely the same virus and have been cultured from blood, semen, and saliva from patients with AIDS or lymphadenopathy syndrome and from asymptomatic individuals from high-risk groups. Antibody to these viruses has been detected in the serum of both asymptomatic and ill individuals from these risk groups. Antibody to HTLV-III/LAV has been detected in 34% to 94% asymptomatic hemophilic patients, a group at high risk for AIDS. In this study, 61% of hemophilic patients had evidence of prior exposure to HTLV-III/LAV. It is not known whether antibody seroconversion occurred in response to exposure to live virus and reflects or resolved infection, or resulted from exposure to inactivated virus in clotting factor replacement products. However, the presence of lymphadenopathy syndrome, thrombocytopenia, herpes zoster, and laboratory evidence of immune dysregulation similar to that associated with AIDS suggests that these patients have been exposed to live virus. Inasmuch as none of these patients has developed the full clinical symptoms of AIDS, and may have future resolution rather than progression of immunologic dysfunction, any speculation regarding the protective nature of various antibody patterns would be premature. Nevertheless, whereas only 4% of antibody-positive patients have normal T4/T8 ratios, 33% of antibody-negative patients have abnormal T4/T8 ratios (Table II). This implies that a spectrum of in vitro laboratory abnormalities, associated with factor VIII concentrate therapy, occurs independent of HTLV-III antibody positivity. In the light of evidence suggesting that antigenemia can exist in asymptomatic antibody-negative individuals, this interpretation is somewhat tentative pending the availability of antigen testing.

### Table II. Relationship of HTLV-III antibody to immunologic abnormalities in hemophilia

<table>
<thead>
<tr>
<th></th>
<th>HTLV-III positive</th>
<th>HTLV-III negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet count/μl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;150,000</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>≥150,000</td>
<td>16</td>
<td>24</td>
</tr>
<tr>
<td>χ² = 6.4; P &lt; 0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4/T8 ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤1.5</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>&gt;1.5</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>χ² = 22.9; P &lt; 0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total T4 lymphocytes/μl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;600</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>≥600</td>
<td>14</td>
<td>21</td>
</tr>
<tr>
<td>χ² = 7.5; P &lt; 0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum IgG (mg/dl)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1,500</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>≤1,500</td>
<td>13</td>
<td>18</td>
</tr>
<tr>
<td>χ² = 9.5; P &lt; 0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Absent</td>
<td>21</td>
<td>22</td>
</tr>
<tr>
<td>χ² = 4.7; P &lt; 0.05</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
HTLV-III/LAV appears to be transmitted by intimate sexual contact and by exposure to blood products, and not by casual contact such as typical exposure to family members other than spouses. None of the parents of hemophilic patients tested had antibody to HTLV-III. The five spouses of hemophilic patients (two antibody positive) reported had negative HTLV-III serologic findings. However, continued follow-up of this group is needed so that accurate counseling can be provided in the future; evidence for infection with HTLV-III via heterosexual transmission is now emerging.

Hemophilic patients given nonheated commercial factor VIII concentrates are at high risk for development of antibody to HTLV-III and associated immunologic abnormalities. Patients given cryoprecipitate prepared from the plasma of Southeastern Wisconsin blood donors appear to be at lower risk. Preliminary evidence suggests that heat treatment of clotting factor concentrates significantly reduces retrovirus infectivity, nonheated concentrates should not be used for treatment of in patients with hemophilia.

REFERENCES

1. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500.


29. Redfield RR, Markham PD, Salahuddin SZ. Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. *JAMA* 1985; 253: 1,571-1,573.

